Human papilloma virus
Human papillomavirus (HPV) is a group of small, non-enveloped, double-stranded DNA viruses of the family Papillomaviridae, comprising more than 200 genotypes that infect cutaneous and mucosal squamous epithelium.
Human papillomavirus (HPV) is a group of small, non-enveloped, double-stranded DNA viruses of the family Papillomaviridae, comprising more than 200 genotypes that infect cutaneous and mucosal squamous epithelium. Roughly 40 types are transmitted through sexual contact, and genital HPV infection is among the most common sexually transmitted infections worldwide. Most infections are transient and cleared by the host immune response; it is persistent infection with a high-risk type that carries disease risk. Low-risk types such as HPV 6 and 11 cause benign warts, while high-risk types — chiefly HPV 16 and HPV 18 — account for the majority of HPV-attributable cancers.
HPV replicates in differentiating squamous epithelium, and its oncogenic potential rests on the viral E6 and E7 proteins, which inactivate the tumor suppressors TP53 and retinoblastoma protein and drive unscheduled cell cycle entry and genomic instability. Integration of viral DNA into the host genome, with loss of the E2 regulatory gene, deregulates E6 and E7 expression and contributes to malignant transformation. Persistent high-risk infection is the necessary cause of essentially all cervical cancer and a substantial share of anal, vulvar, vaginal, penile, and oropharyngeal cancers, placing HPV alongside oncogenic infections such as hepatitis B virus and Helicobacter pylori as a preventable contributor to the global cancer burden. Prophylactic HPV vaccine, including quadrivalent and later multivalent formulations, elicits neutralizing antibodies against the L1 capsid protein and prevents incident infection with the targeted types; together with cervical screening based on high-risk HPV DNA detection, it forms the basis of current cervical cancer prevention. Because vaccine uptake varies widely across countries and populations, much current research addresses real-world effectiveness in adult women, coverage among groups at elevated risk of sexually transmitted infection, and the behavioral and sociocultural determinants of vaccination in low- and middle-income settings.
Where the papers sit
14 papers from the last 6 months study human papilloma virus directly · updated from PubMed 16 Nov 2026
Study type 1 clinical trial · 3 observational · 9 human data · 1 unclassified
Themes 3 themes
-
HPV Vaccination Policy
HPV vaccination policy is moving toward broader, life-course access, including catch-up programs for adults, migrants, and underserved groups. Real-world effectiveness against high-risk HPV DNA supports expansion, while analyses report societal and fiscal returns. Uptake remains uneven across countries and communities, with knowledge, willingness, and access shaping non-uptake. Comparative work also places HPV vaccination within wider infectious-disease immunization programs.
8 papers · 57.1%
-
Cervical Cancer Prevention
Cervical cancer prevention is being linked to both vaccination and post-treatment surveillance. HPV detection after cervical cancer treatment is used to examine recurrence risk, while L2 virus-like-particle and AAV-based approaches address protective immunity. Behavioral and social determinants tools are being adapted to local settings, including Pakistan. The shared direction is integrated prevention and monitoring, although the evidence spans distinct interventions rather than one established strategy.
4 papers · 28.6%
-
Vaccine Formulation and Potency
Vaccine formulation work is shifting toward tighter control of delivery systems and more reliable potency testing. Microfluidic spatial control of mRNA lipid nanoparticles is used to enhance translation and vaccine potency. Chitosanase-based analysis addresses potency determination in chitosan-adjuvanted formulations. Together, these studies emphasize formulation-specific quality control for emerging nucleic-acid and cancer vaccines.
2 papers · 14.3%
Papers
The 14 papers from the last 6 months that study human papilloma virus directly, newest first, by theme and by study type. Study types come from PubMed publication types and MeSH headings.
By theme
HPV Vaccination Policy (8)
- Societal and fiscal gains from HPV vaccination in Poland - return on investment from extending access to HPV vaccination. Journal of medical economics · 10 Sept 2026 PMID 42717549
- A Comparative Policy Analysis of HPV Vaccination Guidelines: Actors, Context, Content, and Process Across Eight Countries. Journal of nursing scholarship : an official publication of Sigma Theta Tau International Honor Society of Nursing · 31 Aug 2026 PMID 42670010
- Real-world effectiveness of HPV vaccination against high-risk type HPV DNA positivity among adult women aged 18 - 45years in China: A matched test-negative design study. Human vaccines & immunotherapeutics · 10 Jul 2026 PMID 42429434
- Assessment of knowledge, attitudes, and behaviors regarding vaccinations among LGBTQIA+ community in Italy. Human vaccines & immunotherapeutics · 25 Jun 2026 PMID 42348835
- Self-reported vaccine uptake across six infectious diseases among gay, bisexual, transgender, and non-binary individuals in Australia: findings from a 2024 national survey. Sexual health · 31 May 2026 PMID 42219251
- Knowledge of HPV and HPV vaccine and its association with vaccination willingness among female undergraduates: A comparative cross-sectional study between healthcare and non-healthcare majors in Chengdu, China. PloS one · 26 May 2026 PMID 42189795
- Catch-up and life-course vaccination policies for adult and adolescent migrants in low-and-middle income countries: A policy analysis. Vaccine · 22 May 2026 PMID 42172819
- Determinants of human papillomavirus vaccine non-uptake among adolescent girls in Ethiopia: evidence from National Immunization Survey. BMJ open · 21 May 2026 PMID 42167948
Cervical Cancer Prevention (4)
- Factors impacting protective immunity conferred by vaccination with adeno-associated virus-like particles displaying human papillomavirus L2 residues 17-36. Journal of virology · 21 Aug 2026 PMID 42627231
- Serum human papilloma virus detection following treatment of cervical cancer: prevalence and its correlation with recurrence. Cancer causes & control : CCC · 25 Jun 2026 PMID 42347892
- From global to local: Developing a context-specific BeSD-HPV tool through cultural and linguistic adaptation in Pakistan. PloS one · 15 Jun 2026 PMID 42296125
- Global Cancer Prevention: Current Approaches and Future Directions. American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting · 26 May 2026 PMID 42190157
Vaccine Formulation and Potency (2)
- Microfluidics-mediated spatial control of mRNA lipid nanoparticles primes translation and enhances vaccine potency. Nature biomedical engineering · 22 Sept 2026 PMID 42773168
- The use of the enzyme chitosanase to enable vaccine potency determination in a formulation containing the adjuvant chitosan. Journal of pharmaceutical sciences · 15 Aug 2026 PMID 42603690
By study type
Clinical trials (1)
- Factors impacting protective immunity conferred by vaccination with adeno-associated virus-like particles displaying human papillomavirus L2 residues 17-36. Journal of virology · 21 Aug 2026 PMID 42627231
Observational studies and case reports (3)
- Serum human papilloma virus detection following treatment of cervical cancer: prevalence and its correlation with recurrence. Cancer causes & control : CCC · 25 Jun 2026 PMID 42347892
- Knowledge of HPV and HPV vaccine and its association with vaccination willingness among female undergraduates: A comparative cross-sectional study between healthcare and non-healthcare majors in Chengdu, China. PloS one · 26 May 2026 PMID 42189795
- Determinants of human papillomavirus vaccine non-uptake among adolescent girls in Ethiopia: evidence from National Immunization Survey. BMJ open · 21 May 2026 PMID 42167948
Human data, design not indexed (9)
- Societal and fiscal gains from HPV vaccination in Poland - return on investment from extending access to HPV vaccination. Journal of medical economics · 10 Sept 2026 PMID 42717549
- A Comparative Policy Analysis of HPV Vaccination Guidelines: Actors, Context, Content, and Process Across Eight Countries. Journal of nursing scholarship : an official publication of Sigma Theta Tau International Honor Society of Nursing · 31 Aug 2026 PMID 42670010
- The use of the enzyme chitosanase to enable vaccine potency determination in a formulation containing the adjuvant chitosan. Journal of pharmaceutical sciences · 15 Aug 2026 PMID 42603690
- Real-world effectiveness of HPV vaccination against high-risk type HPV DNA positivity among adult women aged 18 - 45years in China: A matched test-negative design study. Human vaccines & immunotherapeutics · 10 Jul 2026 PMID 42429434
- Assessment of knowledge, attitudes, and behaviors regarding vaccinations among LGBTQIA+ community in Italy. Human vaccines & immunotherapeutics · 25 Jun 2026 PMID 42348835
- From global to local: Developing a context-specific BeSD-HPV tool through cultural and linguistic adaptation in Pakistan. PloS one · 15 Jun 2026 PMID 42296125
- Self-reported vaccine uptake across six infectious diseases among gay, bisexual, transgender, and non-binary individuals in Australia: findings from a 2024 national survey. Sexual health · 31 May 2026 PMID 42219251
- Global Cancer Prevention: Current Approaches and Future Directions. American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting · 26 May 2026 PMID 42190157
- Catch-up and life-course vaccination policies for adult and adolescent migrants in low-and-middle income countries: A policy analysis. Vaccine · 22 May 2026 PMID 42172819
Unclassified: not yet indexed with MeSH (1)
- Microfluidics-mediated spatial control of mRNA lipid nanoparticles primes translation and enhances vaccine potency. Nature biomedical engineering · 22 Sept 2026 PMID 42773168
Written from 14 PubMed abstracts, each one listed by PMID above. Published: 2026-07-02. Last written: 2026-09-12 by GPT. Reviewed by a human editor on 2026-07-24. Drafted by language models from published abstracts; not medical advice.